We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
In this issue: Knock on effects of the Valsartan recall, the future of AI in healthcare, the history of the...
Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
3DforScience creates 3D scientific animations, medical illustrations, mixed and virtual reality (VR) content for business development and marketing communication applications.
Immumap believes in data-driven decision-making and is based on the foundation of its scientific expertise and know-how.
The high-performance IKA T 25 easy clean homogeniser is ideal for use in research, product development and...
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.
Send me notifications of new editions:
Poteligeo® (mogamulizumab-kpkc) is a monoclonal antibody (mAb) indicated for the treatment of mycosis fungoides and Sézary syndrome in adults.
The Wistar Institute, Penn Medicine and Inovio Pharmaceuticals have announced the receipt of FDA approval for commencement of a first-in-human clinical trial to probe the...
Novus Therapeutics has dosed the first adult subjects in a Phase I clinical trial designed to evaluate the safety and tolerability of OP0201, developed to...
UK-based Summit Therapeutics has started dosing in its Phase III clinical trial of antibiotic ridinilazole for the treatment of Clostridium difficile (C. difficile) infection (CDI).
Boehringer Ingelheim and Eli Lilly have reported positive results from the CAROLINA cardiovascular outcomes trial of Tradjenta (linagliptin) in type 2 diabetes patients.
Voyager Therapeutics will develop and commercialise Neurocrine Biosciences' gene therapy candidates used to treat severe neurological conditions after a collaboration was formed.
Emerald Health Pharmaceuticals (EHP) started patient enrolment for its Phase I clinical trial of EHP-101 for the treatment of patients with multiple sclerosis (MS) and...